Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
Primary objective is to demonstrate the antidepressant efficacy on the Hamilton depression
rating scale (HAM-D) of amibegron (SR58611) 700 mg/day compared to placebo in the treatment
of patients with a recurrent major depressive episode (MDD).
Secondary objective is to assess the safety profile of amibegron 700 mg/d in comparison to
placebo and to assess plasma concentrations of the active metabolite.